• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of treatment with pioglitazone on stroke outcomes: A real ‐world database analysis
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - June 4, 2018 Category: Endocrinology Authors: Christopher Ll Morgan MSc , Silvio E. Inzucchi MD , Jorge Puelles MSc , Sara Jenkins ‐Jones MSc , Craig J. Currie PhD Source Type: research

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - January 8, 2016 Category: Endocrinology Authors: E. Erdmann, S. Harding, H. Lam, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - November 23, 2015 Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research

Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

Observational follow‐up of the PROactive Study: a 6‐year update
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - July 22, 2013 Category: Endocrinology Authors: Erland Erdmann, Eric Song, Robert Spanheimer, Anne‐Ruth van Troostenburg de Bruyn, Alfonso Perez Tags: Original Paper Source Type: research